Rubin Mark A
Institute for Precision Medicine of Weill Cornell Medical College and NewYork-Presbyterian Hospital, New York, NY; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY; Department of Urology, Weill Cornell Medical College, New York, NY; Meyer Cancer Center of Weill Cornell Medical College and NewYork-Presbyterian Hospital, New York, NY.
Urol Oncol. 2015 Feb;33(2):73-4. doi: 10.1016/j.urolonc.2014.10.011. Epub 2014 Nov 20.
The promise of precision cancer medicine is that we will be able to pair clinical and genomic data to provide better and more efficient treatment for cancer care. Although the focus is on the optimal pairing of existing Food and Drug Administration-approved drugs with the patient׳s tumor, precision medicine should also help determine a patient׳s risk for disease progression. Precision medicine will hopefully also lead to improved molecular biomarkers. The specific needs for predictive biomarkers vary significantly based on cancer type. The chief aim for prostate cancer biomarker development is to help distinguish indolent from aggressive disease.
精准癌症医学的前景在于，我们将能够把临床数据与基因组数据相结合，为癌症治疗提供更好、更有效的疗法。尽管重点是将美国食品药品监督管理局（FDA）已批准的现有药物与患者的肿瘤进行最佳匹配，但精准医学还应有助于确定患者疾病进展的风险。精准医学有望还能带来改进的分子生物标志物。预测性生物标志物的具体需求因癌症类型而异。前列腺癌生物标志物开发的主要目标是帮助区分惰性疾病和侵袭性疾病。
